SCHEMBL632916

SCHEMBL632916

O=[N+]([O-])c1ccc(F)c(F)c1Br

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.56
ALDH1A1 P00352 4/20 0.56
TDP1 Q9NUW8 4/20 0.48
ATM Q13315 1/20 0.48
HIF1A Q16665 2/20 0.47
VCAM1 P19320 1/20 0.44
CASP6 P55212 1/20 0.43
TSHR P16473 4/20 0.39
MAPK1 P28482 2/20 0.39
SMN1; SMN2 Q16637 3/20 0.37
CYP3A4 P08684 2/20 0.37
TP53 P04637 1/20 0.37
HPGD P15428 1/20 0.37
CYP1A2 P05177 1/20 0.37
PKM P14618 1/20 0.37
KDM4E B2RXH2 1/20 0.36
LMNA P02545 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
VCP P55072 1/20 0.36
POLB P06746 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29793298 1.00 MAPT (0.56) MAPTALDH1A1TDP1ATMHIF1A
SCHEMBL6978734 0.85 TDP1 (0.50) MAPTALDH1A1TDP1ATMHIF1A
SCHEMBL29711979 0.83 TDP1 (0.48) MAPTALDH1A1TDP1ATMHIF1A
SCHEMBL27557557 0.83 ALDH1A1 (0.56) MAPTALDH1A1TDP1ATMHIF1A
SCHEMBL660797 0.83 TDP1 (0.48) MAPTALDH1A1TDP1ATMHIF1A
SCHEMBL57498 0.80 TDP1 (0.54) MAPTALDH1A1TDP1ATMHIF1A
SCHEMBL29361654 0.80 TDP1 (0.54) MAPTALDH1A1TDP1ATMHIF1A
SCHEMBL34473110 0.80 MAPT (0.53) MAPTALDH1A1TDP1ATMHIF1A
SCHEMBL31645431 0.80 ALDH1A1 (0.53) MAPTALDH1A1TDP1ATMTSHR
SCHEMBL14744408 0.80 ALDH1A1 (0.53) MAPTALDH1A1TDP1ATMHIF1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 36 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12612414-B2 Nitrile SUMO inhibitors and uses thereof CIT THERAPEUTICS, INC. (US) 2026-04-28 US disclosed
EP-4720044-A1 AROMATIC AMIDES AND CONJUGATES THEREOF AS BINDERS TO TEAD Beactica Therapeutics AB (SE) 2026-04-08 EP disclosed
US-20250243183-A1 IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS INCYTE CORPORATION 2025-07-31 US disclosed
US-12312331-B2 Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors INCYTE CORPORATION (US) 2025-05-27 US disclosed
WO-2024240840-A1 AROMATIC AMIDES AND CONJUGATES THEREOF AS BINDERS TO TEAD BEACTICA THERAPEUTICS AB (SE) 2024-11-28 WO disclosed
US-20240360148-A1 NITRILE SUMO INHIBITORS AND USES THEREOF CIT THERAPEUTICS LLC 2024-10-31 US disclosed
EP-4373825-A1 NITRILE SUMO INHIBITORS AND USES THEREOF Suvalent Therapeutics, Inc. (US) 2024-05-29 EP disclosed
US-20240116877-A1 KIT KINASE INHIBITORS AND METHODS OF USE THEREOF DECIPHERA PHARMACEUTICALS, LLC 2024-04-11 US disclosed
US-20240059710-A1 KRAS G12D Inhibitors JACOBIO PHARMACEUTICALS CO., LTD. (CN) 2024-02-22 US disclosed
WO-2024005516-A1 HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF 보로노이 주식회사 2024-01-04 WO disclosed
US-20190284204-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE JANSSEN PHARMACEUTICA NV (BE) 2019-09-19 US disclosed
US-20190284203-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE JANSSEN PHARMACEUTICA NV (BE) 2019-09-19 US disclosed
EP-3386992-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE Janssen Pharmaceutica, N.V. (BE) 2018-10-17 EP disclosed
US-20170283431-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE JANSSEN PHARMACEUTICA NV (BE) 2017-10-05 US disclosed
WO-2017100668-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHODS OF THEIR USE JANSSEN PHARMACEUTICA NV (BE) 2017-06-15 WO disclosed
US-8415272-B2 Quinoline derivatives and their use as fungicides SYNGENTA CROP PROTECTION LLC (US) 2013-04-09 US disclosed
EP-2231614-B1 Quinoline derivatives and their use as fungicides SYNGENTA PARTICIPATIONS AG (CH) 2012-02-22 EP disclosed
US-20100280068-A1 QUINOLINE DERIVATIVES AND THEIR USE AS FUNGICIDES SYNGENTA CROP PROTECTION, INC. (US) 2010-11-04 US disclosed
EP-2231614-A2 QUINOLINE DERIVATIVES AND THEIR USE AS FUNGICIDES Syngenta Participations AG (CH) 2010-09-29 EP disclosed
WO-2009087098-A2 QUINOLINE DERIVATIVES AND THEIR USE AS FUNGICIDES SYNGENTA PARTICIPATIONS AG (CH) 2009-07-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240059710-A1 KRAS G12D Inhibitors KRAS, NRAS, HRAS MAPT 2627/4885ALDH1A1 2783/4885TDP1 3627/4885
US-20190284204-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE ABL1, BTK, MYLK2 MAPT 4289/4885ALDH1A1 4003/4885TDP1 244/4885
US-12312331-B2 Imidazolyl pyrimidinylamine compounds as CDK2 inhibitors CDK2, CDK4, CDK2AP2 MAPT 3217/4885ALDH1A1 3723/4885TDP1 1699/4885
US-20240360148-A1 NITRILE SUMO INHIBITORS AND USES THEREOF SUMO1, SUMO3, SUMO2 MAPT 3041/4885ALDH1A1 1529/4885TDP1 818/4885
US-20240116877-A1 KIT KINASE INHIBITORS AND METHODS OF USE THEREOF KIT, MAP3K19, DCK MAPT 4318/4885ALDH1A1 2553/4885TDP1 1017/4885
US-12612414-B2 Nitrile SUMO inhibitors and uses thereof SUMO1, SUMO3, PSMB6 MAPT 4404/4885ALDH1A1 1299/4885TDP1 1726/4885
US-20170283431-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE ABL1, BTK, MYLK2 MAPT 4289/4885ALDH1A1 4003/4885TDP1 244/4885
US-20190284203-A1 INHIBITORS OF BRUTON'S TYROSINE KINASE AND METHOD OF THEIR USE ABL1, BTK, MYLK2 MAPT 4289/4885ALDH1A1 4003/4885TDP1 244/4885
US-20100280068-A1 QUINOLINE DERIVATIVES AND THEIR USE AS FUNGICIDES CYP1A1, CYP3A7, CYP1A2 MAPT 3438/4885ALDH1A1 350/4885TDP1 949/4885
US-20250243183-A1 IMIDAZOLYL PYRIMIDINYLAMINE COMPOUNDS AS CDK2 INHIBITORS CDK2, CDK4, CDK2AP2 MAPT 3217/4885ALDH1A1 3723/4885TDP1 1699/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.